Journal article

An institutional audit of the use of novel drugs in pediatric oncology

Justin Lee, Lynn Gillam, Sarah Kouw, Maria C McCarthy, Jordan R Hansford

Cancer Reports | WILEY | Published : 2021


BACKGROUND: Significant challenges persist in treating children with rare, relapsed, or refractory malignancies. Novel molecularly targeted drugs promise improved outcomes for these children with reduced toxicity. However, there is often limited evidence to substantiate their clinical efficacy and guide their use. This raises issues for clinical decision-making, ethical concerns surrounding equity of access to these often-expensive agents, and the management of families' expectations for cure. This audit evaluated the off-label use of novel drugs and associated clinical outcomes in order to guide the development of future clinical and ethical guidelines. AIM: To evaluate the patterns in the ..

View full abstract


Awarded by Victorian Cancer Agency

Awarded by Royal Children's Hospital Foundation

Funding Acknowledgements

Department of Human Services and Operational Infrastructure Support Program; Victorian Cancer Agency, Grant/Award Number: #HSR15034; Royal Children's Hospital Foundation, Grant/Award Number: 2015-500